Fate Therapeutics (FATE) Earnings Analysis
Fate Therapeutics (FATE) has no confirmed upcoming earnings date. Last quarter (2026-02-26) it beat with EPS -0.27 USD vs -0.27 USD est (0%). It has beaten estimates in 3/3 recent quarters (100%). Trailing P/E -2.37.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does FATE next report earnings?
No confirmed upcoming earnings date is currently scheduled for FATE. This page updates as the calendar is published.
FATE earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-26 | -0.27 USD | -0.27 USD | 0% | Beat |
| 2025-11-13 | -0.27 USD | -0.29 USD | +6.9% | Beat |
| 2025-03-05 | -0.31 USD | -0.44 USD | +29.5% | Beat |
Beat rate: 3/3 (100%) over reported quarters with consensus data.
FATE valuation and analyst view
| Trailing P/E | -2.37 |
|---|---|
| Trailing EPS | -1.08228 USD |
| Price / book | 1.72 |
| Dividend yield | 0.00% |
| Market cap | 0.30B |
| Analyst consensus | Buy (16 buy / 13 hold / 2 sell) |
| Avg price target | 5.5 USD |
Related research pages
Frequently asked questions
When is Fate Therapeutics (FATE)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for FATE. This page updates as the calendar is published.
Did FATE beat earnings last quarter?
In its 2026-02-26 report, FATE posted EPS of -0.27 USD versus a -0.27 USD estimate — a beat of 0%.
What is FATE's earnings track record?
Over the last 3 reported quarters with consensus data, FATE beat estimates 3 times (100%).
What is FATE's current P/E ratio and EPS?
FATE trades at a trailing P/E of -2.37 on trailing EPS of -1.0822820086984792 USD.
What do analysts rate FATE?
Analyst consensus is "Buy" across 31 ratings (0 strong buy, 16 buy, 13 hold, 2 sell, 0 strong sell). Average 12-month price target: 5.5 USD.